Search
for
Sort by
Research 31–60 of 284
- Alopecia/hair loss in all patients treated with trastuzumab and paclitaxel: myth or reality?
- Impact of anticancer therapy on the quality of life of Sudanese patients with breast cancer at Khartoum oncology hospital
- Anti-invasive effects of minoxidil on human breast cancer cells: combination with ranolazine
- Global Trends in Research of Androgen Receptor Associated With Breast Cancer From 2011 to 2020: A Scientometric Analysis
- Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
- Safety assessment of cyclin-dependent kinase 4/6 inhibitors and comparison of time to adverse events
- Sacituzumab Govitecan-Hziy (Trodelvy™)
- Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
- Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation
- Cold Atmospheric Plasma for Breast Cancer
- Hair loss severity and its impact on quality of life in patients suffering from androgenic alopecia: A one-year cross-sectional study
- Molecular Targeted Agents and Biologic Therapies for Non-small Cell Lung Cancer
- NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
- Diagnostic Value of VDR in Bone Metastasis and Prognosis of Patients with Breast Cancer and Expression Correlation between Vitamin D Receptor and Hairless Protein
- Clinicopathological factors associated with trichilemmal cysts
- Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
- Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review
- Evaluation of Androgen Receptor Expression and Its Association with Clinicopathological Features in Iraqi Women with Breast Cancer
- Local heroes or villains: tissue-resident memory T cells in human health and disease
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Permanent chemotherapy-induced alopecia: Case report and review of the literature
- Pathogenesis and treatment options for chemotherapy‐induced alopecia: a systematic review
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Síndrome PRIDE: una práctica forma de identificar los efectos adversos cutáneos de los inhibidores del EGFR
- Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis
- Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
- A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol
- Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database
- Efficacy and tolerability of scalp cooling in preventing alopecia during (neo)adjuvant chemotherapy for breast cancer
- Novel drugs of United States Food and Drug Administration approved in 2024